Excitotoxicity Markers and the Clinical-radiological Progression After
Excitotoxicity Markers and the Clinical-radiological Progression After a Demyelinating Event: a Prospective Pilot Study
What it found
We found no results in the registry or in papers.
This trial finished 14 years ago. We found no results in the registry or in any paper that cites it.
What was tested
Treatment tested
- Aspartic acid
What it measured
Main measures
glutamate concentration (in nM)
baseline
Who could take part
MS (type not specified) · 18 to 60
Show the full criteria
Inclusion criteria
* Man or woman between 18 and 60 years old. * Patient with one or more type of inflammatory events of Central system suggestive of demyelinating disease (multiple sclerosis, neuromyelitis optical Devic extensive myelitis) * No treatment with corticosteroids for less than 1 month * Need for a lumbar puncture performed in the etiologic * Need a brain MRI performed within the etiologic * Patient who signed informed consent
Exclusion criteria
* Secondary progressive MS * Any cons-indication for lumbar puncture * Any contra-indication to MRI * Minor patient or patient major under guardianship
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
Multiple sclerosis (MS) is an inflammatory disease of the central nervous system, beginning most often in subjects aged 20-40 years. In France, thanks to recent studies reported during general states of MS in 2006, the prevalence is estimated at 65.5 / 100,000 population (96.3 / 100,000 women and 41.9 / 100,000 men) and incidence at 7.91 per 100,000. In Lower Normandy, the incidence of MS is estimated to 4.45 / 100,000 inhabitants or 60 new cases per year. The primary objective of this pilot study is to assess the levels of glutamate and aspartate (excitotoxicity markers) and their repercussions on the clinical and radiological outcome in 40 patients experiencing an event demyelinating central nervous system.
Loading reviews and guidelines…
Related trials
- Cannabis (THC vs. CBD) in Multiple Sclerosis
Phase 2 · Recruiting
Still running
- ANTIBIOBONTA - Assessment of the interest of a peri-operative antibiot
Phase 3 · Not yet recruiting
Still running
- A study to asses the effects of Nabiximols on spasticity associated wi
Phase 3 · Completed
No results found
- Evaluation of the Effect of Nabiximols Oromucosal Spray on Clinical Me
Phase 3 · Stopped early
Stopped
- Trial to Evaluate the Effect of Nabiximols Oromucosal Spray on Clinica
Phase 3 · Completed
Missed its main goal
- Safety and Effectiveness of Nabiximols Oromucosal Spray as Add-on Ther
Phase 3 · Stopped early
Stopped
History
Started
Sept 2007
Main results due
Feb 2012
Finished
Feb 2015